Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Could endocrine therapy plus a CDK4/6 inhibitor offer a viable chemo-sparing option in hormone receptor (HR)-positive/HER2-positive breast cancer?

Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

Discover essential antibody purification methods, from affinity chromatography to ion exchange chromatography, for research ...

The gastrin-releasing peptide receptor (GRPR) is overexpressed in various cancers, including prostate cancer, breast cancer, small cell and non–small cell lung cancer, uterine and ovarian cancer, ...

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...